Ask AI
ProCE Banner Activity

Expert Q&A: Optimizing BTK Inhibitor Use Across the CLL/SLL Treatment Landscape

Clinical Thought

This expert Q&A explores how evolving data and consensus guidelines on BTK inhibitors, including their role alongside CAR T-cell therapy, optimal sequencing after covalent BTK inhibitor failure, and selection in patients with comorbidities, can inform personalized treatment decisions in patients with CLL/SLL.

Released: January 21, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This educational activity is intended for hematologists, medical oncologists, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia / small lymphocytic lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select individualized frontline therapy for patients with CLL/SLL, based on current evidence, recommendations outlined in NCCN Guidelines, expert guidance, and patient medical history and preferences

  • Plan optimal treatment strategies for patients with R/R CLL that integrate recommendations outlined in the NCCN Guidelines, emerging targeted therapy approaches, sequencing therapy based on response to and tolerance of prior therapy, and mechanisms of resistance

  • Devise comprehensive patient education and supportive care strategies for targeted therapy–associated AEs to improve clinical outcomes